Eagle Asset Management Inc. Boosts Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Eagle Asset Management Inc. boosted its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 4.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 273,789 shares of the biotechnology company's stock after acquiring an additional 12,480 shares during the quarter. Eagle Asset Management Inc. owned 0.49% of Repligen worth $38,522,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Andra AP fonden acquired a new stake in shares of Repligen in the 2nd quarter valued at approximately $25,000. International Assets Investment Management LLC acquired a new stake in Repligen in the second quarter valued at approximately $33,000. UMB Bank n.a. grew its stake in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after buying an additional 130 shares during the last quarter. Lazard Asset Management LLC increased its holdings in shares of Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock worth $36,000 after buying an additional 136 shares in the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 127 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Up 0.6 %

NASDAQ RGEN traded up $0.82 on Friday, hitting $142.58. 556,879 shares of the company were exchanged, compared to its average volume of 706,303. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13. The company has a current ratio of 10.44, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.99 billion, a PE ratio of -385.34, a PEG ratio of 4.27 and a beta of 0.96. The stock has a fifty day moving average of $140.26 and a 200-day moving average of $143.44.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the business posted $0.23 EPS. As a group, analysts forecast that Repligen Co. will post 1.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. UBS Group reduced their price objective on Repligen from $205.00 to $185.00 and set a "buy" rating on the stock in a research report on Wednesday, July 31st. Stephens reaffirmed an "overweight" rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price objective for the company. Royal Bank of Canada reissued an "outperform" rating and set a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Finally, Wolfe Research began coverage on shares of Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating for the company. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Repligen presently has an average rating of "Moderate Buy" and a consensus target price of $190.25.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the business's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company's stock, valued at $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.20% of the stock is owned by insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.